臍帶血是造血幹細胞移殖可行的幹細胞來源。然而從單一臍帶血中能取得的造血幹細胞數量極低，限制了對病患的臍帶血移殖療。
在本研究中，我們使用兩種不同的培養方式，各別是二維平面與三維立體培養法。對2維平面培養，我們使用具有細胞外間質(ECM)與寡糖胜肽蛋白質(如Fibronectin與CS-1)或者是化學官能基(如氨基)固定化接枝的的表面改殖材料進行培養。除此之外，在三維立體培養法上，我們也發展了使用膜過濾法的造血幹細胞直接體外培養法；我們研究如何使用奈米接枝對材料或膜表面改殖，並模仿骨髓幹細胞龕環境，以適用於體外造血幹細胞培養。
對直接體外培養法而言，使用具有COOH基接枝的PU膜具有較高的幹細胞增殖倍率；對膜過濾直接體外培養法而言，潤洗液必需含有超過50%的低血小板血清。使用膜過濾直接體外培養法可藉由簡單的臍帶血分離操作提供三維培養環境與高幹細胞增殖倍率。在二維培養方面，高表面接枝密度氨基不適合培養造血幹細胞，我們發現對造血幹細胞培養而言，氨基具有最適化表面接枝密度。除此之外，在最適化接枝密度下且具有良好表面接枝度控制的細胞外間質表面改殖，有較高的幹細胞增殖倍率。總結而言，PS-FN、PS-CS1-H與PS-Ozone-AMA-0.3mM是出色的造血幹細胞培養生醫材料。

Umbilical cord blood (UCB) is a promising source of stem cells for hematopoietic stem cell (HSC) transplantation. However, the low number of HSCs that can be obtained from a single UCB donor limits the transplantation of UCB for patients. We investigated two culture methods of HSCs, 2D and 3D culture. The 2D-culture used the surface-modified materials immobilized extracellular matrix (ECM) and oligopeptides such as fibronectin and CS-1, or nano-segments having amino group. We also developed a direct ex vivo HSC expansion method followed by 3D-culture of HSCs on the membranes. We investigated how to create and mimic the bone marrow niche for the expansion of HSCs by using nano-segments and ECMs on the surface of the membranes and culture materials. In the direct ex vivo expansion of HSCs, PU membranes having nano-segments of carboxylic acid showed higher expansion fold of HSCs among surface-modified PU membranes investigated in this study. In this case, the rinsing solution should contain platelet-poor plasma (PPP) more than 50%. The direct ex vivo expansion of HSCs from UCB filtered through membranes can provide a simple 3-D culture method of HSCs and a high fold ex vivo expansion of HSCs with a simple operation. In 2D-culture of HSCs, high surface density of amino group on the culture dishes was not favor, and the optimal surface density of amino group was found for HSC expansion. There found optimal amino groups with well controlled surface density and ECMs (CS1-H and Fibronectin) with optimal surface density for high expansion folds of HSCs in 2-D culture. In summary, PS-FN, PS-CS1-H and PS-Ozone-AMA-0.3mM dishes are excellent cultivation materials of HSCs.

[1] Becker AJ, McCulloch EA, Till JE. "Cytological demonstration of the clonal
nature of spleen colonies derived from transplanted mouse marrow cells". Nature
1963; 197: 452–4.
[2] A. Higuchi, S.T. Yang, P.T. Li, Y. Chang, E.M. Tsai, Y.H. Chen, Y.J. Chen, H.C.
Wang, S.T. Hsu, “Polymeric Materials for Ex vivo Expansion of Hematopoietic
Progenitor and Stem Cells”, Polym Rev. (2009) 49, 181 - 200.
[3] Toma, J.G., Akhavan, M., Fernandes, K.J., Barnabe-Heider, F., Sadikot, A.,
Kaplan, D.R. & Miller, F.D. Isolation of multipotent adult stem cells from the
dermis of mammalian skin. Nature Cell Biology 2001; 3, 778–784.
[4] Wang, H.S., Hung, S.C., Peng, S.T., Huang, C.C., Wei, H.M., Guo, Y.J., Fu,
Y.S., Lai, M.C. & Chen, C.C. Mesenchymal stem cells in the Wharton’s jelly of
the human umbilical cord. Stem Cells 2004; 22, 1330–1337.
[5] Coleman SR. Overview of structural fat grafting. In: Coleman SR, Mazzola RF
(eds) Fat injection from filling to regeneration. Quality Medical Publishing, St.
Louis, MO 2009; pp 93–110
[6] Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators. J Cell
Biochem 2006; 98(5):1076–1084
[7] Scadden DT. The stem-cell niche as an entity of action. Nature 2006;
441:1075–1079
[8] Horwitz EM, Gordon PL, Koo WK et al. Isolated allogeneic bone
marrow-derivedmesenchymal cells engraft and stimulate growth in children with
osteogenesis imperfecta: Implications for cell therapy of bone. Proc Natl Acad
Sci U S A 2002; 99:8932– 8937.
[9] Arinzeh TL, Peter SJ, Archambault MP et al. Allogeneic mesenchymal stem cells
regenerate bone in a critical-sized canine segmental defect. J Bone Joint Surg Am
2003; 85-A:1927–1935.
[10] Pittenger MF, Mackay AM, Beck SC et al. Multilineage potential of adult
human mesenchymal stem cells. Science 1999; 284:143–147.
[11] Pountos I, Jones E, Tzioupis C et al. Growing bone and cartilage: The role of
mesenchymal stem cells. J Bone Joint Surg Br 2006; 88:421– 426.
[12] Jeffrey M, Gimble, Adam J. Katz and Bruce A. Bunnell. Adipose-derived stem
cells for regenerative medicine. Circulation Research 2007; 100, 1249-1260
[13] Mitchell JB, McIntosh K, Zvonic S, Garrett S, Floyd ZE, Kloster A, Di
Halvorsen Y, Storms RW, Goh B, Kilroy G, Wu X, Gimble JM. The
immunophenotype of human adipose derived cells: temporal changes in stromal127
and stem cell-associated markers. Stem Cells 2006; 24: 376–385.
[14] McIntosh K, Zvonic S, Garrett S, Mitchell JB, Floyd ZE, Hammill L, Kloster A,
Halvorsen YD, Ting JP, Storms RW, Goh B, Kilroy G, Wu X, Gimble JM. The
immunogenicity of human adipose derived cells: temporal changes in vitro. Stem
Cells 2006; 24:1245–1253.
[15] Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD,
Moorman MA, Simonetti DW, Craig S, Marshak DR. Multilineage potential of
adult human mesenchymal stem cells. Science. 1999; 284: 143–147.
[16] Favre, G., et al., Differences between graft product and donor side effects
following bone marrow or stem cell donation. Bone Marrow Transplant, 2003.
32(9):873-80.
[17] Bosi, A. and B. Bartolozzi, Safety of bone marrow stem cell donation: a review.
Transplant Proc, 2010. 42(6):2192-4.
[18] Gratwohl, A., et al., Predictability of hematopoietic stem cell transplantation
rates. Haematologica, 2007. 92(12):1679-86.
[19] Hamidieh, A.A., et al., Autologous stem cell transplantation as treatment
modality in a patient with relapsed pancreatoblastoma. Pediatr Blood Cancer,
2010. 55(3) 573-6.
[20] Higuchi, A., et al., Separation of hematopoietic stem cells from human
peripheral blood through modified polyurethane foaming membranes. Journal of
Biomedical Materials Research Part A, 2008. 85A(4):853-861.
[21] Cohen, Y. and A. Nagler, Umbilical cord blood transplantation--how, when and
for whom? Blood Rev, 2004. 18(3)167-79.
[22] T. Reya, S.J. Morrison, M.F. Clarke, I.L. Weissman, “Stem cells, cancer, and
cancer stem cells”, Nature (2001) 414, 105-111.
[23] S.T. Yang, “Separation and ex vivo expansion of hematopoietic stem cells from
human blood by membrane filtration and magnetic associated sorting method”,
NCU Master thesis (2009)
[24] H. Ema, H. Takano, K. Sudo, H. Nakauchi, “In vitro self-renewal division of
hematopoietic stem cells”, J. Exp. Med. (2000) 192, 1281-1288.
[25] N. Fox, G. Priestley, T. Papayannopoulou, K. Kaushansky, “Thrombopoietin
expands hematopoietic stem cells after transplantation”, J. Clin. Invest. (2002)
110, 389-394.
[26] J. Audet, C.L. Miller, S. Rose-John, J.M. Piret, C.J. Eaves, “Distinct role of
gp130 activation in promoting self-renewal divisions by mitogenically
stimulated murine hematopoietic stem cells”, Proc. Natl. Acad. Sci. USA (2001)
98, 1757-1762.
[27] G. Gollner, G. Bug, B. Rupilius, C. Peschel, C. Huber, H.G. Derigs, “Regulatory
elements of the leukaemia inhibitory factor (LIF) promoter in murine bone
128
marrow stromal cells”, Cytokine (1999) 11, 656-663.
[28] Rocha V, Cornish J, Sievers EL, et al. Comparison of outcomes of unrelated
bone marrow and umbilical cord blood transplants in children with acute
leukemia. Blood. 2001;97:2962–2971.
[29] Frassoni F, Podesta M, Maccario R, et al. Cord blood transplantation provides
better reconstitution of hematopoietic reservoir compared with bone marrow
transplantation. Blood. 2003;102:1138–1141.
[30] Laughlin MJ, Eapen M, Rubinstein P, et al. Outcomes after transplantation of
cord blood or bone marrow from unrelated donors in adults with leukemia. N
Engl J Med. 2004;351:2265–2275.
[31] Rocha V, Labopin M, Sanz G, et al. Transplants of umbilical-cord blood or bone
marrow from unrelated donors in adults with acute leukemia. N Engl J Med.
2004;351:2276–2285.
[32] M.A. Moore, “Cytokine and chemokine networks influencing stem cell
proliferation, differentiation, and marrow homing”, J. Cell. Biochem. (2002)
Suppl. 38, 29-38.
[33] P. Feugier, D.Y. Jo, J.H. Shieh, K.L. MacKenzie, S. Rafii, R.G. Crystal, M.A.S.
Moore, “Ex vivo expansion of stem and progenitor cells in co-culture of
mobilized peripheral blood CD34+ cells on human endothelium transfected with
adenovectors expressing thrombopoietin, c-kit ligand, and Flt-3 ligand”, J.
Hematother. Stem Cell Res. (2002) 11, 127-138.
[34] Z. Ivanovic, P. Dello Sbarba, F. Trimoreau, J.L. Faucher, V. Praloran, “Primitive
human HPCs are better maintained and expanded in vitro at 1 percent oxygen
than at 20 percent”, Transfusion (2000) 40, 1482-1488.
[35] G. Migliaccio, A.R. Migliaccio, J.W. Adamson, “In vitro differentiation of
human granulocyte/macrophage and erythroid progenitors: comparative analysis
of the influence of recombinant human erythropoietin, G-CSF, GM-CSF, and
IL-3 in serum-supplemented and serum-deprived cultures”, Blood (1988) 72,
248-256.
[36] M.A. Socinski, S.A. Cannistra, A. Elias, K.H. Antman, L. Schnipper, J.D.
Griffin, “Granulocyte-macrophage colony stimulating factor expands the
circulating haemopoietic progenitor cell compartment in man”, Lancet (1988) 1,
1194-1198.
[37] Y.W. Choi, H.H. Park, D.J. Oh, “Ex vivo Expansion of Hematopoietic Cells
from CD34+ Cord Blood Cells in Various Culture Conditions”, Biotechnol.
Bioprocess Eng. (2010) 15, 157-166
[38] K. Li, M. Yang, A.C. Lam, F.W. Yau, P.M.P. Yuen, “Effects of flt-3 ligand in
combination with TPO on the expansion of megakaryocytic progenitors”, Cell
129
Transplant. (2000) 9, 125-131.
[39] L. Lazzari, S. Lucchi, P. Rebulla, L. Porretti, G. Puglisi, L. Lecchi, G. Sirchia,
“Long-term expansion and maintenance of cord blood haematopoietic stem cells
using thrombopoietin, Flt3-ligand, interleukin (IL)-6 and IL-11 in a serum-free
and stroma-free culture system”, Br. J. Haematol. (2001) 112, 397-404.
[40] P.H. Shaw, M. Olszewski, M. Kletzel, “Expansion of megakaryocyte precursors
and stem cells from umbilical cord blood CD34+ cells in collagen and liquid
culture media”, J. Hematother. Stem Cell Res. (2001) 10, 391-403.
[41] R.J. Su, X.B. Zhang, K. Li, M. Yang, C.K. Li, T.F. Fok, A.E. James, H. Pong,
P.M.P. Yuen, “Platelet-derived growth factor promotes ex vivo expansion of
CD34+ cells from human cord blood and enhances longterm culture-initiating
cells, non-obese diabetic/severe combined immunodeficient repopulating cells
and formation of adherent cells”, Br. J. Haematol. (2002) 117, 735-746.
[42] McNiece I, Briddell R. Ex vivo expansion of hematopoietic progenitor cells and
mature cells. Exp Hematol. (2001);29:3–11.
[43] Yvette van Hensbergena, Laurus F. Schippera. Ex vivo culture of human CD34t
cord blood cells with thrombopoietin (TPO) accelerates platelet engraftment in a
NOD/SCID mouse model Experimental . Hematology 34 (2006) 943–950
[44] S.M. Watt, J.Y.H. Chan, “CD164- a novel sialomucin on CD34+ cells”, Leuk.
Lymphoma (2000) 37, 1-25.
[45] M.A. Dao, J.A. Nolta, “CD34: to select or not to select? That is the question”,
Leukemia (2000) 14, 773-776.
[46] J. Zhu, S.G. Emerson, “Hematopoietic cytokines, transcription factors and
lineage commitment”, Oncogene (2002) 21, 3295-3313.
[47] E.A. de Wynter, A.J.B. Emmerson, N.G. Testa, “Properties of peripheral blood
and cord blood stem cells”, Baillieres Best Pract. Res. Clin. Haematol. (1999) 12,
1-17.
[48] H. Sutherland, C. Eaves and A. Eaves, “Characterisation and partial purification
of human marrow cells capable of initiating long-term hematopoiesis in vitro”,
Blood (1989) 74, 1563-1569.
[49] W. Craig, R. Kay, R.L. Cutler, P.M. Lansdorp, “Expression of Thy-1 on human
haematopoietic progenitor cells”, J. Exp. Med. (1999) 177, 1331-1342.
[50] H. Mayani, P.M. Lansdorp, “Thy-1 expression is linked to functional properties
of primitive hematopoietic progenitor cells from human umbilical cord blood”,
Blood (1994) 83, 2410-2417.
[51] C.M. Baum, I.L. Weissman, A.S. Tsukamoto, A.M. Buckle, B. Peault, “Isolation
of a candidate human hematopoietic stem-cell population”, Proc. Natl. Acad. Sci.
USA (1992) 89, 2804-2808.
[52] E.A. de Wynter, C. Hart, L.H. Coutinho, D. Gagen, J. Chang, D. Buck, N.G.
130
Testa, “Analysis of human hemopoietic cells isolated with the novel AC133
antibody”, Exp. Hematol. (1998) 26, 739-739.
[53] H.J. Sutherland, P.M. Lansdorp, D.H. Henkelman, A.C. Eaves, C.J. Eaves,
“Functional characterization of individual human hematopoietic stem cells
cultured at limiting dilution on supportive marrow stromal layers”, Proc. Natl.
Acad. Sci. USA (1990) 87, 3584-3588.
[54] C. Udomsakdi, C.J. Eaves, H.J. Sutherland, P.M. Lansdorp, “Separation of
functionally distinct subpopulations of primitive human hematopoietic cells
using Rhodamine-123”, Exp. Hematol. (1991) 19, 338-342.
[55] S. Siena, M. Bregni, B. Brando, N. Belli, F, Ravagnani, L. Gandola, A.C. Stern,
P.M. Lansdorp, G. Bonadonna, A.N. Gianni, “Flow cytometry for the clinical
estimation of circulating hematopoietic progenitors for autologous
transplantation in cancer patients”, Blood (1991) 77, 400-409.
[56] J. Seita, I.L. Weissman, “Hematopoietic stem cell: self-renewal versus
differentiation”, WIREs Syst. Biol. Med. (2010)
[57] G. Somlo, J. Doroshow, S. Forman et al., “High-dose chemotherapy and stem
cell rescue for the treatment of primary highrisk breast cancer: prognostic
indicators of overall survival and progression-free survival”, Proc. Am. Soc. Clin.
Oncol. (1995) 14, 113.
[58] K. Antman, L. Ayash, A. Elias, C. Wheeler, M. Hunt, J.P. Eder, B.A. Teicher, J.
Critchlow, J. Bibbo, L.E. Schnipper, E. Frei, “A phase II study of high-dose
cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in
women with measurable advanced breast cancer responding to standard-dose
therapy”, J. Clin. Oncol. (1992) 10, 102-110.
[59] A.A. Ross, B.W. Cooper, H.M. Lazarus, W. Mackay, T.J. Moss, N. Ciobanu, M.S.
Tallman, M.J. Kennedy, N.E. Davidson, D Sweet, C. Winter, L. Akard, J. Jansen,
E. Copelan, R.C. Meagher, R.H. Herzig, T.R. Klumpp, D.G. Kahn, N.E. Warner,
“Detection and viability of tumor cells in peripheral blood stem cell collections
from breast cancer patients using immunocytochemical and clonogenic assay
techniques”, Blood (1993) 82, 2605-2610.
[60] A.A. Ross, M. Loudovaris, B. Hazelton, C.H. Weaver, L. Schwartzberg, J.G.
Bender, “Immunocytochemical analysis of tumor cells in pre- and post-culture
peripheral blood progenitor cell collections from breast cancer patients”, Exp.
Hematol. (1995) 23, 1478-1483.
[61] W. Brugger, K.J. Bross, M. Glatt, F. Weber, R Mertelsmann, L. Kanz,
“Mobilization of tumor cells and hematopoietic progenitor cells into peripheral
blood of patients with solid tumors”, Blood (1994) 83, 636-640.
[62] R.J. Berenson, W.I. Bensinger, D. Kalamasz et al., “Avidin–biotin
immunoadsorption: a technique to purify cells and its potential applications, In:
131
Gale RP, Champlin R (eds)” Progress in Bone Marrow Transplantation. Liss:
New York (1989) 423-428.
[63] D.F. Stroncek, S.K. Fautsch, L.C. Lasky, D.D. Hurd, N.K.C. Ramsay, J.
Mccullough, “Adverse reactions in patients transfused with cryopreserved
marrow”, Transfusion (1991) 31, 521-526.
[64] M.J. Styler, D.L. Topolsky, P.A. Crilley, V. Covalesky, R. Bryan, S. Bulova, I
Brodsky, “Transient high grade heart block following autologous bone marrow
infusion”, Bone Marrow Transplant. (1992) 10, 435-438.
[65] E.J. Shpall, C.F. LeMaistre, K. Holland, E. Ball, R.B. Jones, R. Saral, C. Jacobs,
S. Heimfeld, R. Berenson, R. Champlin, “A prospective randomized trial of
buffy coat versus CD34-selected autologous bone marrow support in high-risk
breast cancer patients receiving high-dose chemotherapy”, Blood (1997) 90,
4313-4320.
[66] S. Miltenyi, S. Guth, A. Radbruch, “Isolation of CD34+ hematopoietic
progenitor cells by high-gradient magnetic cell sorting (MACS)”, Hematopoietic
Stem Cells: The Mulhouse Manual (1994) 201-213.
[67] D.J. Richel, H.E. Johnsen, J. Canon, T. Guillaume, M.R. Schaafsma, C.
Schenkeveld, S.W. Hansen, I. McNiece, A.J. Gringeri, R. Briddell, C. Ewen, R.
Davies, J. Freeman, S. Miltenyi, M. Symann, “Highly purified CD34(+) cells
isolated using magnetically activated cell selection provide rapid engraftment
following high-dose chemotherapy in breast cancer patients”, Bone Marrow
Transpl. (2000) 25, 243-249.
[68] M.J. Fulwyler, “Electronic Separation of Biological Cells by Volume”, Science
(1965) 150, 910-911.
[69] R.G. Sweet, “High Frequency Recording with Electrostatically Deflected Ink
Jets”, Rev. Sci. Instr. (1965) 36, 131-136.
[70] M.A.V. Dilla, M.J. Fulwyler, I.U. Boone, “Volume distribution and separation of
normal human leucocytes”, Proc. Soc. Exp. Biol. Med. (1967) 125, 367-370.
[71] W.A. Bonner, H.R. Hulett, R.G. Sweet, L.A. Herzenberg, “Fluorescence
Activated Cell Sorting”, Rev. Sci. Instr. (1972) 43, 404-409.
[72] K.W. Johnson, A. Dooner, P. J. Quesenberry, “Fluorescence activated cell sorting:
A window on the stem cell”, Curr. Pharm. Biotechnol. (2007) 8, 133-139.
[73] M. Assenmacher, R. Manz, S. Miltenyi, A. Scheffold, A. Radbruch,
“Fluorescence-activated cytometry cell sorting based on immunological
recognition”, Clin. Biochem. (1995) 28, 39-40.
[74] M.R. Loken, Immunofluorescence Techniques in Flow Cytometry and Sorting
(1990) 2nd edition, Wiley.
[75] K. Kato, A. Radbruch, “Isolation and characterization of CD34+ hematopoietic
stem cells from human peripheral blood by high-gradient magnetic cell sorting”,
132
Cytometry (1993) 14, 384-392.
[76] S. Miltenyi, W. Muller, W. Weichel, A. Radbruch, “High-gradient magnetic cell
separation with MACS”, Cytometry (1990) 11, 231-238.
[77] E.A. de Wynter, L.H. Coutinho, X. Pei et al., “Comparison of purity and
enrichment of CD34+ cells from bone marrow, umbilical cord and peripheral
blood (primed for apheresis) using five separation systems”, Stem Cells (1995)
13, 524-532.
[78] I. McNiece, R. Briddell, G. Stoney et al., “Large-scale isolation of CD34+ cells
using the Amgen Cell Selection Device results in high levels of purity and
recovery”, J. Hematother. (1997) 6, 1-11.
[79] A. Higuchi, Y. Shindo, Y. Gomei, T. Mori, T. Uyama, A. Umezawa, “Cell
separation between mesenchymal progenitor cells through porous polymeric
membranes”, J. Biomat. Sci. Polym. Edn. Part B: Applied Biomater. (2005) 74,
511-519.
[80] A. Higuchi, S. Yamamiya, B.O. Yoon, N. Sakurai, M. Hara, “Peripheral blood
cell separation through surface-modified polyurethane membranes”, J. Biomed.
Mater. Res. A (2004) 68, 34-42.
[81] A. Higuchi, Y. Tsukamoto, “Cell separation of hepatocytes and fibroblasts
through surface-modified polyurethane membranes”, J. Biomed. Mate. Res. A,
(2004) 71, 470-479.
[82] A. Higuchi, A. Iizuka, Y. Gomei, T. Miyazaki, M. Sakurai, Y. Matsuoka, S.
Hayashi, “Separation of CD34+ cells from human peripheral blood through
polyurethane membranes”, J. Biomed. Mater. Res. Part A (2006) 78, 491-499.
[83] H. Komai, Y. Naito, K. Fujiwara, Y. Takagaki, Y. Noguch, Y. Nishimura, “The
protective effect of a leukocyte removal filter on the lung in open-heart surgery
for ventricular septal defect”, Perfusion (1998) 13, 27-34.
[84] M. Yasutake, M. Sumita, S. Terashima, Y. Tokushima, Y. Nitadori, T.A.
Takahashi, “Stem cell collection filter system for human placental/umbilical cord
blood processing”, Vox Sang (2001) 80, 101-105.
[85] M. Muller-Steinhardt, H. Hennig, H. Kirchner and P. Schlenke, “Prestorage
WBC filtration of RBC units with soft-shell filters: Filtration performance and
impact on RBCs during storage for 42 days”, Transfusion (2002) 42, 153-158.
[86] A. Higuchi, S.T. Yang, P.T. Li, H. Chen, R.C. Ruaan, W.Y. Chen, Y. Chang, Y.
Chang, E.M. Tsai, Q.D. Ling, H.C. Wang, S.T. Hsu, “Separation of
hematopoietic stem and progenitor cells from human peripheral blood through
polyurethane foaming membranes modified with several amino acids”, J. Appl.
Polym. Sci. (2009) 114, 671-679.
[87] P.V. O’Donnell, B. Myers, J. Edwards, K. Loper, P. Rhubart, S.J. Noga, “CD34
selection using three immunoselection devices: Comparison of T-cell depleted
133
allografts”, Cytotherapy (2001) 3, 483-488.
[88] K. Sazama, P. Holand, “Transfusion-induced graft-versus-host disease”, In:
Ganatty G, editor. Immunobiology of Transfusion Medicine, New York: Marcel
Dekker (1994) 631-656.
[89] J. Debelak, M.J. Shlomchik, E.L. Snyder, D. Cooper, S. Seropian, J. McGuirk, B.
Smith, D.S. Krause, “Isolation and flow cytometric analysis of T-cell-depleted
CD34+ PBPCs”, Transfusion (2000) 40, 1475-1481.
[90] S. Florian, K. Sonneck, A.W. Hauswirth, M.T. Krauth, G.H. Schernthaner, W.R.
Sperr, P. Valent, “Detection of molecular targets on the surface of CD34+/CD38-
stem cells in various myeloid malignancies”, Leuk. Lymphoma (2006) 47,
207-222.
[91] Patrick CW,Mikos AG, McIntire LV, editors. Frontiers in tissue
engineering.Oxford: Pergamon; 1998.
[92] Rosso F, Giordano A, Barbarisi M, Barbarisi A. From cell-ECM interactions to
tissue engineering. J Cell Physiol 2004;199:174–80.
[93] Langer R, Vacanti JP. Tissue engineering. Science 1993;260:920–6.
[94] Abatangelo G, Brun P, Radice M, Cortivo R, Auth MKH. Tissue engineering. In:
Barbucci R, editor. Integrated biomaterial science. New York: Kluwer Academic;
2001. p. 885–945.
[95] Putnam AJ, Mooney DJ. Tissue engineering using synthetic extracellular
matrices. Nat Med 1996;2:824–6.
[96] Daley WP, Peters SB, Larsen M. Extracellular matrix dynamics in development
and regenerative medicine. J Cell Sci 2008;121:255–64.
[97] Rozario T, DeSimone DW. The extracellular matrix in development and
morphogenesis: a dynamic view. Dev Biol 2010;341:126–40.
[98] William P. Daley, Sarah B. Peters and Melinda Larsen. Extracellular matrix
dynamics in development and regenerative medicine. Journal of Cell Science
121, 255-264 Published by The Company of Biologists 2008
[99] Rosso F, Marino G, Giordano A, BarbarisiM,Parmeggiani D, Barbarisi A. Smart
materials as scaffolds for tissue engineering. J Cell Physiol 2005;203:465–70.
[100] Moroni L, de Wijn JR, van Blitterswijk CA. Integrating novel technologies
to fabricate smart scaffolds. J Biomater Sci Polym Ed 2008;19:543–72.
[101] Mano JF, Silva GA, Azevedo HS, Malafaya PB, Sousa RA, Silva SS, Boesel
LF, Oliveira JM, Santos TC, Marques AP, ves NM, Reis RL. Natural origin
biodegradable systems in tissue engineering and regenerative medicine: present
status and some moving trends. J R Soc Interface 2007;4:999–1030.
[102] Chi H. Lee, Anuj Singla, Yugyung Lee, “Biomedical applications of
collagen”, International Journal of Pharmaceutics, Vol. 221, 1-22, (2001)
[103] CC Tate, DA Shear, MC Tate et al. ,”Laminin and fibronectin scaffolds
134
enhance neural stem cell transplanted into the injured brain”, Tissue Eng Regan
Med, Vol. 3, 208,(2009)
[104] CC Tate, DA Shear, MC Tate et al. ,”Fibronectin promotes survival and
migration of primary neural stem cell transplanted into the traumatically injured
mouse brain”, Cell Transplantation, Vol. 11, 238,(2002)
[105] Gutman A, Kornblihtt AR. Identification of a third region of cellspecific
alternative splicing in human fibronectin mRNA. Proc Natl Acad Sci USA
1987;84:7179–82.
[106] Ruoslahti E, Pierschbacher MD. New perspectives in cell adhesion:RGD and
integrins. Science 1987;238:491–7.
[107] Bhadriraju K, Hansen LK. Hepatocyte adhesion, growth and differentiated
function on RGD-containing proteins. Biomaterials 2000;21:267–72.
[108] Mooney D, Hansen L, Vacanti J, Langer R, Farmer S, Ingber D. Switching
from differentiation to growth in hepatocytes: control by extracellular matrix. J
Cell Physiol 1992;151:497–505.
[109] Hansen LK, Mooney DJ, Vacanti JP, Ingber DE. Integrin binding and cell
spreading on extracellular matrix act at different points in the cell cycle to
promote hepatocyte growth. Mol Biol Cell 1994;5:967–75.
[110] Rosemblatt M, Vuillet-Gaugler MH, Leroy C, Coulombel L. Coexpression of
two fibronectin receptors, VLA-4 and VLA-5, by immature human
erythroblastic precursor cells. J Clin Invest 1991;87:6–11.
[111] Teixido J, Hemler ME, Greenberger JS, Anklesaria P. Role of beta 1 and beta
2 integrins in the adhesion of human CD34hi stem cells to bone marrow stroma.
J Clin Invest 1992;90:358–67.
[112] Kerst JM, Sanders JB, Slaper-Cortenbach IC, Doorakkers MC, Hooibrink B,
van Oers RH, et al. Alpha 4 beta 1 and alpha 5 beta 1 are differentially expressed
during myelopoiesis and mediate the adherence of human CD34+ cells to
fibronectin in an activationdependent way. Blood 1993;81:344–51.
[113] Felding-Habermann B, Cheresh DA (October 1993). "Vitronectin and its
receptors". Curr. Opin. Cell Biol. 5 (5): 864–8
[114] Hynda K. Kleinman and George R. Martin NIDCR, NIH Review Matrigel:
Basement membrane matrix with biological activity. Stem Cancer.2005.05.004
[115] N Rangappa, A Romero, KD Nelson, “Laminin-coated poly(L-lactide)
filaments induce robust neurite growth while providing directional orientation.”,
J Biomed Master Res, Vol. 51, 625, (2000)
[116] Schofield, R. (1978). The relationship between the spleen colony-forming
cell and the haemopoietic stem cell. Blood Cells 4, 7-25.
[117] Scadden, D. T. (2006). The stem-cell niche as an entity of action. Nature 441,
1075-1079.
135
[118] Nilsson, S. K., Johnston, H. M., Whitty, G. A., Williams, B., Webb, R. J.,
Denhardt, D. T., Bertoncello, I., Bendall, L. J., Simmons, P. J. and Haylock, D. N.
(2005). Osteopontin, a key component of the hematopoietic stem cell niche and
regulator of primitive hematopoietic progenitor cells. Blood 106, 1232-1239.
[119] Moore, K. A. and Lemischka, I. R. (2006). Stem cells and their niches.
Science 311, 1880-1885.
[120] Li, L. and Xie, T. (2005). Stem cell niche: structure and function. Annu. Rev.
Cell Dev.Biol. 21, 605-631.
[121] Gupta, P., Oegema, T. R., Jr, Brazil, J. J., Dudek, A. Z., Slungaard, A. and
Verfaillie, C. M. (1998). Structurally specific heparan sulfates support primitive
human hematopoiesis by formation of a multimolecular stem cell niche. Blood
92, 4641-4651.
[122] Jensen, U. B., Lowell, S. and Watt, F. M. (1999). The spatial relationship
between stem cells and their progeny in the basal layer of human epidermis: a
new view based on whole-mount labelling and lineage analysis. Development
126, 2409-2418.
[123] Klees, R. F., Salasznyk, R. M., Kingsley, K., Williams, W. A., Boskey, A. and
Plopper, G. E. (2005). Laminin-5 induces osteogenic gene expression in human
mesenchymal stem cells through an ERK-dependent pathway. Mol. Biol. Cell 16,
881-890.
[124] Klees, R. F., Salasznyk, R. M., Kingsley, K., Williams, W. A., Boskey, A. and
Plopper, G. E. (2005). Laminin-5 induces osteogenic gene expression in human
mesenchymal stem cells through an ERK-dependent pathway. Mol. Biol. Cell 16,
881-890.
[125] Nuttelman CR, Tripodi MC, Anseth KS. Synthetic hydrogel niches that
promote hMSC viability. Matrix Biol 2005;24:208–18.
[126] Feng Q, Chai C, Jiang XS, LeongKW,Mao HQ. Expansion of engrafting
human hematopoietic stem/progenitor cells in three-dimensional scaffolds with
surface-immobilized fibronectin. J Biomed Mater Res A 2006;78:781–91.
[127] Gerecht S, Burdick JA, Ferreira LS, Townsend SA, Langer R, Vunjak-
Novakovic G. Hyaluronic acid hydrogel for controlled self-renewal and
differentiation of human embryonic stem cells. Proc Natl Acad Sci USA
2007;104:11298–303.
[128] Chang CF, Lee MW, Kuo PY, Wang YJ, Tu YH, Hung SC. Threedimensional
collagen fiber remodeling by mesenchymal stem cells requires the
integrin-matrix interaction. J Biomed Mater Res A 2007;80:466–74.
[129] K.N. Chua, C. Chai, , P.C. Lee, Y.N. Tang, S. Ramakrishna, K.W. Leong,
H.Q. Mao, “Surface-aminated electrospun nanofibers enhance adhesion and
expansion of human umbilical cord blood hematopoietic stem/progenitor cells”,
136
Biomaterials (2006) 27, 6043-6051.
[130] K.N. Chua, C. Chaib, P.C. Lee, S. Ramakrishna, K.W. Leong, H.Q. Mao,
“Functional nanofiber scaffolds with different spacers modulate adhesion and
expansion of cryopreserved umbilical cord blood hematopoietic stem/progenitor
cells”, Exp. Hematol. (2007) 35, 771-781.
[131] D. Bonnet, “Biology of human bone marrow stem cells”, Clin. Exp. Med.
(2003) 3, 140-149.
[132] M. Takagi, “Cell processing engineering for ex-vivo expansion of
hematopoietic cells”, J. Biosci. Bioeng. (2005) 99, 189-196.
[133] C.L. McDowell, E.T. Papoutsakis, “Serum increases the CD13 receptor
expression, reduces the transduction of fluid-mechanical forces, and alters
themetabolism of HL60 cells cultured in agitated bioreactors”, Biotechnol.
Bioeng. (1998) 60, 259-268.
[134] C.E. Sandstrom et al., “Review: serum-free media for cultures of primitive
and mature hematopoietic cells”, Biotechnol. Bioeng. (1994) 43, 706-733.
[135] G. Almeida-Porada et al., “Evaluation of serum-free culture conditions able
to support the ex vivo expansion and engraftment of human hematopoietic stem
cells in the human-to-sheep xenograft model”, J. Hematother. Stem Cell Res.
(2000) 9, 683-693.
[136] Q. Feng, C. Chai, X-S Jiang, K.W. Leong, H-Q Mao, “Expansion of
engrafting human hematopoietic stem/progenitor cells in three-dimensional
scaffolds with surface-immobilized fibronectin”, J. Biomed. Mater. Res. (2006)
78A, 781-791.
[137] E. Fuchs, T. Tumbar, G. Guasch, “Socializing with the neighbors: Stem cells
and their niche”, Cell (2004) 116, 769 –778.
[138] I.R. Lemischka, K.A. Moore, “Stem cells: Interactive niches”, Nature (2003)
425, 778-779.
[139] J.A. LaIuppa, T.A. McAdams, E.T. Papoutsakis, W.M. Miller, “Culture
materials affect ex vivo expansion of hematopoietic progenitor cells”, J. Biomed.
Mater. Res. (1997) 36, 347-359.
[140] X.S. Jiang, C. Chai, Y. Zhang, R-X Zhuo, H-Q Mao, K.W. Leong,
“Surface-immobilization of adhesion peptides on substrate for ex vivo expansion
of cryopreserved umbilical cord blood CD34(+) cells”, Biomaterials (2006) 27,
2723-2732.
[141] S. Neussa, C. Apel, P. Buttler, B. Denecke, A. Dhanasingh, X. Ding, D.
Grafahrend, A. Groger, K. Hemmrich, A. Herr, W. Jahnen-Dechent, S.
Mastitskaya, A. Perez-Bouza, S. Rosewick, J. Salber, M. Woltje, M. Zenke,
“Assessment of stem cell/biomaterial combinations for stem cell-based tissue
engineering”, Biomaterials (2008) 29, 302–313.
137
[142] R. Langer, D.A. Tirrell, “Designing materials for biology and medicine”,
Nature (2004) 428, 487–492.
[143] S. Janjanin, W.J. Li, M.T. Morgan, R.M. Shanti, R.S. Tuan, “Mold-shaped,
nanofiber scaffold-based cartilage engineering using human mesenchymal stem
cells and bioreactor”, J. Surg. Res. (2008) 149, 47-56.
[144] J. Venugopal, S. Low, A.T. Choon, S. Ramakrishna, “Interaction of cells and
nanofiber scaffolds in tissue engineering”, J. Biomed. Mater. Res. (2008) 84B,
34-48.
[145] J.M. Dang, K.W. Leong, “Myogenic induction of aligned mesenchymal stem
cell sheets by culture on thermally responsive electrospun nanofibers”, Tissue
Eng. Part A (2008) 14, 639-648.
[146] W.J. Li, Y.J. Jiang, R.S. Tuan, “Cell-nanofiber-based cartilage tissue
engineering using improved cell seeding, growth factor, and bioreactor
technologies”, Tissue Eng. Part A (2008) 14, 639-648.
[147] I. Han, K.J. Shim, J.Y. Kim, Y.K. Sung, M. Kim, I-K IKang, J.C. Kim,
“Effect of poly(3-hydroxybutyrate-co-3-hydroxyvalerate) nanofiber matrices
cocultured with hair follicular epithelial and dermal cells for biological wound
dressing”, Art. Org. (2007) 31, 801-808.
[148] S.I. Jeong, I.D. Jun, M.J. Choi, Y.C. Nho, Y.M. Lee, H. Shin, “Development
of electroactive and elastic nanofibers that contain polyaniline and
poly(L-lactide-co-epsilon-caprolactone) for the control of cell adhesion”,
Macromol. Biosci. (2008) 8, 627-637.
[149] K. Ma, C.K. Chan, S. Liao, W.Y.K. Hwang, Q. Feng, S. Ramakrishna,
“Electrospun nanofiber scaffolds for rapid and rich capture of bone
marrow-derived hematopoietic stem cells”, Biomaterials (2008) 29, 2096-2103.
[150] J.N. Ournakis, J. Eldridge, M. Demcheva, R.C. Muise-Helmericks,
“Poly-N-acetyl glucosamine nanofibers regulate endothelial cell movement and
angiogenesis: Dependency on integrin activation of Ets1”, J. Vascular Res. (2008)
45, 222-232.
[151] J.A. van Aalst, C.R. Reed, L. Han, T. Andrady, M. Hromadka, S. Bernacki, K.
Kolappa, J.B.J. Collins, E.G. Loboa, “Cellular incorporation into electrospun
nanofibers - Retained viability, proliferation, and function in fibroblasts”, Annals
Plastic Surg. (2008) 60, 577-583.
[152] W.S. Li, Y. Guo, H. Wang, D. Shi, C. Liang, Z. Ye, F. Qing, J. Gong,
“Electrospun nanofibers immobilized with collagen for neural stem cells
culture”, J. Mater. Sci. Mater. Med. (2008) 19, 847-854.
[153] F. Tian, H. Hosseinkhani, M. Hosseinkhani, M. Hosseinkhani, A.
Khademhosseini, Y. Yokoyama, G.G. Estrada, H. Kobayashi, “Quantitative
analysis of cell adhesion on aligned micro- and nanofibers”, J. Biomed. Mater.
138
Res. (2008) 84A, 291-299.
[154] K.N. Chua, C. Chaib, P.C. Lee, S. Ramakrishna, K.W. Leong, H.Q. Mao,
“Functional nanofiber scaffolds with different spacers modulate adhesion and
expansion of cryopreserved umbilical cord blood hematopoietic stem/progenitor
cells”, Exp. Hematol. (2007) 35, 771-781.
[155] Venugopal J, Low S, Choon AT, Ramakrishna S. Interaction of cells and
nanofiber scaffolds in tissue engineering. J Biomed Mater Res B Appl Biomater
2008;84:34–48.
[156] Ma Z, Kotaki M, Inai R, Ramakrishna S. Potential of nanofiber matrix as
tissue-engineering scaffolds. Tissue Eng 2005;11:101–9.
[157] Vasita R, Katti DS. Nanofibers and their applications in tissue engineering.
Int J Nanomed 2006;1:15–30.
[158] Vince Beachley, Xuejun Wen. Polymer nanofibrous structures: Fabrication,
biofunctionalization, and cell interactions. Progress in Polymer Science 35
(2010) 868–892
[159] Ma Z, He W, Yong T, Ramakrishna S. Grafting of gelatin on electrospun
poly(caprolactone) nanofibers to improve endothelial cell spreading and
proliferation and to control cell Orientation. Tissue Eng 2005;11:1149–58.
[160] Koh HS, Yong T, Chan CK, Ramakrishna S. Enhancement of neurite
outgrowth using nano-structured scaffolds coupled with laminin. Biomaterials
2008;29:3574–82.
[161] M. Kizling, S.G. Jaras, Appl. Catal. A: Gen. 147 (1996) 1.
[162] P.J.C. Chappel, J.R. Brown, G.A. George, H.A. Willis, Surf. Interf. Anal. 17
(1991) 143.
[163] P.K. Chu, J.Y. Chen, L.P. Wang, N. HuangPlasma-surface modification of
biomaterials. Materials Science and Engineering R 36 (2002) 143–206
[164] H. J. Griesser, R. C. Chatelier, T. R. Gengenbach, G. Johnson, J. G. Steele, J.
Biomater. Sci. Polym. Ed. 1994, 5,531.
[165] A. A. Meyer-Plath, B. Finke, K. Schroder, A. Ohl, Surf.Coat. Technol. 2003,
174, 877.
[166] R.Daw, I.M. Brook, A. J. Devlin, R. D. Short, E. Cooper,G.J. Leggett, J.
Mater. Chem. 1998, 8, 2583.
[167] Y. Ito, M. Kajihara, Y. Imanishi, J. Biomed. Mater. Res.1991, 25, 1325.
[168] Y. Kinoshita, T. Kuzuhara, M. Kirigakubo, M. Kobayashi,K. Shimura, Y.
Ikada, Biomaterials 1993, 14, 546.
[169] A. Kishida, Y. Ueno, I. Maruyama, M. Akashi, Biomaterials 1994, 15, 1170.
[170] C. J. van Delden, J. P. Lens, R. P. H. Kooyman, G. H. M. Engbers, J. Feijen,
Biomaterials 1997, 18, 845.
[171] P. Favia, F. Palumbo, R. D’Agostino, S. Lamponi, A. Magnani, R. Barbucci,
139
Plasmas Polym. 1998, 3, 77.
[172] T.M. exter, T.D. Allen, L.G. Lajtha, “Conditions controlling the proliferation
of haemopoietic stem cells in vitro”, J. Cell Physiol. (1977) 91, 335–344.
[173] K.P. Schofield, M.J. Humphries, E. de Wynter, N. Testa, J.T. Gallagher, “The
effect of alpha 4beta 1-integrin binding sequences of fibronectin on growth of
cells from human hematopoietic progenitors”, Blood (1998) 91, 3230–3238.
[174] C.M. Verfaillie, J.B. McCarthy, P.B. McGlave, “Differentiation of primitive
human multipotent hematopoietic progenitors into single lineage clonogenic
progenitors is accompanied by alterations in their interaction with fibronectin”, J.
Exp. Med. (1991) 174, 693–703.
[175] F. Li, S.D. Redick, H.P. Erickson, V.T. Moy, “Force measurements of the
α5β1 integrin–fibronectin interaction”, Biophys. J. (2003) 84, 1252–1262.
[176] E. Evans, “Looking inside molecular bonds at biological interfaces with
dynamic force spectroscopy”, Biophys. Chem. (1999) 82, 83–97.
[177] [129] R. Bhatia, A.D. Williams, H.A. Munthe, “Contact with fibronectin
enhances preservation of normal but not chronic myelogenous leukemia
primitive hematopoietic progenitors”, Exp. Hematol. (2002) 30, 324–332.
[178] B.M.M. Sagar, S. Rentala, P.N.V. Gopal, S. Sharma, A. Mukhopadhyay,
“Fibronectin and laminin enhance engraftibility of cultured hematopoietic stem
cells”, Biochem. Biophys. Res. Comm. (2006) 350, 1000–1005.
[179] C.M. Orschell-Travcoff, K. Hiatt, R.N. Dagher, S. Rice, M.C. Yoder, F.F.
Srour, “Homing and engraftment potential of Sca-1+Lin- cells fractionated on the
basis of adhesion molecule expression and position in cell cycle”, Blood (2000)
96, 1380–1387.
[180] M. Rosemblatt, M.H. Vuillet-Gaugler, C. Leroy, L. Coulombel,
“Coexpression of two fibronectin receptors, VLA-4 and VLA-5, by immature
human erythroblastic precursor cells”, J. Clin. Invest. (1991) 87, 6–11.
[181] J. Teixido, M.E. Hemler, J.S. Greenberger, P. Anklesaria, “Role of beta 1 and
beta 2 integrins in the adhesion of human CD34hi stem cells to bone marrow
stroma”, J. Clin. Invest. (1992) 90, 358–367.
[182] J.M. Kerst, J.B. Sanders, I.C. Slaper-Cortenbach, M.C. Doorakkers, B.
Hooibrink, R.H. van Oers, A.E. von dem Borne, C.E. van der Schoot, “Alpha 4
beta 1 and alpha 5 beta 1 are differentially expressed during myelopoiesis and
mediate the adherence of human CD34+ cells to fibronectin in an
activationdependent way”, Blood (1993) 81, 344–351.
[183] D.H. Ryan, B.L. Nuccie, C.N. Abboud, J.M. Winslow, “Vascular cell
adhesion molecule-1 and the integrin VLA-4 mediate adhesion of human B cell
precursors to cultured bone marrow adherent cells”, J. Clin. Invest. (1991) 88,
995–1004.
140
[184] D.A. Williams, M. Rios, C. Stephens, V.P. Patel, “Fibronectin and VLA-4 in
haematopoietic stem cell-microenvironment interactions”, Nature (1991) 352,
438–441.
[185] N. Yanai, C. Sekine, H. Yagita, M. Obinata, “Roles for integrin very late
activation antigen-4 in stroma-dependent erythropoiesis”, Blood (1994) 83,
2844–2850.
[186] Vermeulen, M., Le Pesteur, F., Gagnerault, M. C., Mary, J. Y., Sainteny, F.
and Lepault, F. (1998). Role of adhesion molecules in the homing and
mobilization of murine hematopoietic stem and progenitor cells. Blood 92,
894-900.
[187] Nilsson, S. K., Johnston, H. M., Whitty, G. A., Williams, B., Webb, R. J.,
Denhardt, D. T., Bertoncello, I., Bendall, L. J., Simmons, P. J. and Haylock, D. N.
(2005). Osteopontin, a key component of the hematopoietic stem cell niche and
regulator of primitive hematopoietic progenitor cells. Blood 106, 1232-1239.
[188] Stier, S., Ko, Y., Forkert, R., Lutz, C., Neuhaus, T., Grunewald, E., Cheng, T.,
Dombkowski, D., Calvi, L. M., Rittling, S. R. et al. (2005). Osteopontin is a
hematopoietic stem cell niche component that negatively regulates stem cell pool
size. J. Exp. Med. 201, 1781-1791.
[189] T. Yokota, K. Oritani, H. Mitsui, K. Aoyama, J. Ishikawa, H. Sugahara, I.
Matsumura, S. Tsai, Y. Tomiyama, Y. Kanakura, Y. Matsuzawa,
“Growth-supporting activities of fibronectin on hematopoietic stem/progenitor
cells in vitro and in vivo: structural requirement for fibronectin activities of CS1
and cell-binding domains”, Blood (1998) 91, 3263–3272.
[190] H. Park, C. Cannizzaro, G. Vunjak-Novakovic, R. Langer, C.A. Vacanti, O.C.
Farokhzad, Nanofabrication and microfabrication of functional materials for
tissue engineering, Tissue Eng. 13 (2007) 1867–1877.
[191] L.G. Griffith, M.A. Swartz, Capturing complex 3D tissue physiology in vitro,
Nat. Rev. Mol. Cell Biol. 7 (2006) 211–224.
[192] B.S. Kim, D.J. Mooney, Development of biocompatible synthetic
extracellular matrices for tissue engineering, Trends Biotechnol. 16 (1998)
224–230.
[193] K. Saha, J.F. Pollock, D.V. Schaffer, K.E. Healy, Designing synthetic
materials to control stem cell phenotype, Curr. Opin. Chem. Biol. 11 (2007)
381–387.
[194] Nicole H. Romano, Debanti Sengupta, Cindy Chung, Sarah C. Heilshorn.
Protein-engineered biomaterials: Nanoscale mimics of the extracellular matrix.
Biochimica et Biophysica Acta 1810 (2011) 339–349
[195] C.H. Cho, J.F. Eliason, H.W. Matthew, “Application of porous
glycosaminoglycan-based scaffolds for expansion of human cord blood stem
141
cells in perfusion culture”, J. Biomed. Mater. Res. A. (2008) 86, 98-107.
[196] K. Franke, T. Pompe, M. Bornhauser, C. Werner, “Engineered matrix
coatings to modulate the adhesion of CD133+ human hematopoietic progenitor
cells”, Biomaterials (2007) 28, 836–843.
[197] L. Healy, D. May, K. Gale et al., “The stem cell antigen CD34 functions as a
regulator of hemopoietic cell adhesion” Proc. Natl. Acad. Sci. USA (1995) 92,
12240–12244.
[198] M. Fackler, D.S. Krause O.M. Smith et al., “Full length but not truncated
CD34 inhibits hematopoietic cell differentiation of M1 cells”, Blood (1995) 85,
3040–3047.
[199] C.I. Civin, L.C. Strauss, C. Brovall et al., “Antigenic analysis of
hematopoiesis. III. A haematopoietic progenitor cell surface antigen defined by a
monoclonal antibody raised against KG-1a cells”, J. Immunol. (1984) 133,
157–165.
[200] A. Gianni, S. Siena, M. Bregni, “Granulocyte-macrophage colony
stimulating factor to harvest circulating haemopoietic stem cells for
autotransplantation”, Lancet (1989) ii, 580—585.
[201] S. Siena, M. Bregni, B. Brando, “Circulation of CD34+ haematopoietic stem
cells in the peripheral blood of high dose cyclophosphamide treated patients:
enhancement by intravenous recombinant human granulocyte-macrophage
colony stimulating factor”, Blood (1989) 74, 1905—1914.
[202] D. Sutherland, A. Keating, R. Nayar et al., “Sensitive detection and
enumeration of CD34+ cells in peripheral and cord blood by flow cytometry”,
Exp Hematol (1994) 22, 1003–1010.
[203] B. Thilaganathan, K.H. Nicolaides, G. Morgan, “Subpopulations of
CD34-positive haemopoietic progenitors in fetal blood”, Br. J. Haematol. (1994)
87, 634–636.
[204] J.W. Gratama, A. Orfao, D. Barnett, B. Brando, A. Huber, G. Janossy, H.E.
Johnsen, M. Keeney, G.E. Marti, F. Preijers, G. Rothe, S. Serke, D. R. Sutherland,
C.E. Van der Schoot, G. Schmitz, S. Papa, “Flow Cytometric Enumeration of
CD341 Hematopoietic Stem and Progenitor Cells”, Cytometry (1998) 34,
128–142.
[205] J.G. Bender, K. Unverzagt, D. Walker, “Guidelines for determination of
CD34+ cells by flow cytometry: Application to the harvesting and transplantation
of peripheral blood stem cells”, The Mulhouse Manual (1994) 31–43.
[206] M.J. Borowitz, K.L. Guenther, K.E. Schultz, G.T. Stelzer,
“Immunophenotyping of acute leukemia by flow cytometry: Use of CD45 and
right angle light scatter to gate on leukemic blasts in three color analysis”, Am. J.
Clin. Pathol. (1993) 100, 534–540.
142
[207] C.H. Chen, W. Lin, S. Shye, R. Kibler, K. Grenier, D. Recktenwald,
L.W.M.M. Terstappen, “Automated enumeration of CD34+ cells in peripheral
blood and bone marrow”, J. Hematother. (1994) 3, 3–13.
[208] G. Fritsch, D. Printz, M. Stimpfl, M.N. Dworzak, V. Witt, U. Po‥tschger, P.
Buchinger, “Quantification of CD34+ cells: Comparison of methods”,
Transfusion (1997) 37, 775–784.
[209] K. Gutensohn, S. Serke, U. Cassens, J. Fischer, G. Fritsch, S. Fruehauf, H.S.P.
Garritsen, W. Gebauer, R. Haas, H.G. Ho‥ffkes, A. Humpe, H.D. Kleine, R.
Moog, J. Riggert, G. Rothe, P. Schlenke, G. Schmitz, T. Tonn, B. Wo‥rmann, B.L.
Ziegler, “Durchflubzytometrische Analyse CD34- exprimierender
ha‥matopoetischer Zellen in Blut und Zytafereseprodukten”, Infusionsther
Transfusionsmed (1996) 23 (Suppl 2), 1–23.
[210] J.W. Gratama, A. Orfao, D. Barnett, B. Brando, A. Huber, G. Janossy, H.E.
Johnsen, M. Keeney, G.E. Marti, F. Preijers, G. Rothe, S. Serke, D.R. Sutherland,
C.E. Van der Schoot, G. Schmitz, S. Papa, “Flow Cytometric Enumeration of
CD34+ Hematopoietic Stem and Progenitor Cells”, Cytometry (1998) 34,
128–142.
[211] D.R. Sutherland, L. Anderson, M. Keeney, R. Nayar, I. Chin-Yee, “The
ISHAGE guidelines for CD34+ cell determination by flow cytometry”, J.
Hematother. (1996) 5, 213–226.
[212] G. Olesen, H. Tonder, M.S. Holm, P. Hokland, “Long-term culture of
hematopoietic stem cells – validating the stromal component of the CAFC
assay”, Cytotherapy (2001) 3, 107–116.
[213] J.E. Dick, “Normal and leukemic human stem cells assayed in SCID mice”,
seminars in IMMUNOLOGY (1996) 8, 197–206.
[214] Sato T, Arai K, Ishiharajima S, Asano G. Role of glycosaminoglycan and
fibronectin in endothelial cell growth. Exp Mol Pathol. 1987 Oct;47(2):202-10.
[215] K. Geissler, T. Wagner, “Cytokine combinations for the in vivo and ex vivo
expansion of hematopoietic progenitor cells”, Acta Med. Austriaca (2000) 27,
21-24.
[216] F. Keil, F. Elahi, H.T. Greinix, G. Fritsch, N. Louda, A.L. Petzer, E. Prinz, T.
Wagner, P. Kalhs, K. Lechner, K. Geissler, “Ex vivo expansion of long-term
culture initiating marrow cells by IL-10, SCF, and IL-3”, Transfusion (2002) 42,
581-587.
[217] T. Kimura, J.F. Wang, H. Minamiguchi, H. Fujiki, S. Harada, K. Okuda, H.
Kaneko, S. Yokota, K. Yasukawa, T. Abe, Y. Sonoda, “Signal through gp130
activated by soluble interleukin (IL)-6 receptor (R) and IL-6 or IL-6R/IL-6
fusion protein enhances ex vivo expansion of human peripheral blood-derived
hematopoietic progenitors”, Stem Cells (2000) 18, 444-452.
143
[218] T. Wagner, G. Fritsch, R. Thalhammer, P. Hocker, G. Lanzer, K. Lechner, K.
Geissler, “IL-10 increases the number of CFU-GM generated by ex vivo
expansion of unmanipulated human MNCs and selected CD34+ cells”,
Transfusion (2001) 41, 659-666.
[219] F.N. Karanu, B. Murdoch, L. Gallacher, D.M. Wu, M. Koremoto, S. Sakano,
M. Bhatia, “The notch ligand jagged-1 represents a novel growth factor of
human hematopoietic stem cells”, J. Exp. Med. (2000) 192, 1365-1372.
[220] M. Masuya, N. Katayama, N. Hoshino, H. Nishikawa, S. Sakano, H. Araki,
H. Mitani, H. Suzuki, H. Miyashita, K. Kobayashi, K. Nishii, N. Minami, H.
Shiku, “The soluble Notch ligand, Jagged-1, inhibits proliferation of CD34+
macrophage progenitors”, Int. J. Hematol. (2002) 75, 269-276.
[221] N. Banu, M. Rosenzweig, H. Kim, J. Bagley, M. Pykett,
“Cytokineaugmented culture of haematopoietic progenitor cells in a novel
three-dimensional cell growth matrix”, Cytokine (2001) 13, 349–358.
[222] J. Bagley, M. Rosenzweig, D.F. Marks, M.J. Pykett, “Extended culture of
multipotent hematopoietic progenitors without cytokine augmentation in a novel
three-dimensional device”, Exp. Hematol. (1999) 27, 496 –504.
[223] Y. Li, T. Ma, D.A. Kniss, S.T. Yang, L.C. Lasky, “Human cord cell
hematopoiesis in three-dimensional nonwoven fibrous matrices: In vitro
simulation of the marrow microenvironment”, J. Hematother. Stem Cell Res.
(2001) 10, 355–368.
[224] H.S. Kim, J.B. Lim, Y.H. Min, S.T. Lee, C.J. Lyu, E.S. Kim, H.O. Kim, “Ex
vivo expansion of human umbilical cord blood CD34+ cells in a collagen
bead-containing 3-dimensional culture system”, Int. J. Hematol. (2003) 78,
126 –132.
[225] S. Huang, D.E. Ingber, “The structural and mechanical complexity of
cell-growth control”, Nat. Cell Biol. (1999) 1, E131–E138.
[226] Michael R. Doran, Brandon D. Markway, Ian A. Aird, Andrew S. Rowlands,
Peter A. George, Lars K. Nielsen, Justin J. Cooper-White. Surface-bound stem
cell factor and the promotion of hematopoietic cell expansion. Biomaterials 30
(2009) 4047–4052.
[227] Satoko Kishimoto , Shingo Nakamura , Shin-ichiro Nakamura , Hidemi
Hattori , Fumie Oonuma , Yasuhiro Kanatani , Yoshihiro Tanaka , Yasuji Harada ,
Masahiro Tagawa , Tadaaki Maehara , Masayuki Ishihara. Cytokine-immobilized
microparticle-coated plates for culturing hematopoietic progenitor cells.
Journal of Controlled Release 133 (2009) 185–190
[228] Vipuil Kishore, James F. Eliason, Howard W. T. Matthew. Covalently
immobilized glycosaminoglycans enhance megakaryocyte progenitor expansion
and platelet release. J Biomed Mater Res Part A: 96A: 682-692, 2011.
144
[229] Joan E. Nichols , Joaquin Cortiella , Jungwoo Lee , Jean A. Niles , Meghan
Cuddihy , Shaopeng Wang , Joseph Bielitzki , Andrea Cantu , Ron Mlcak ,
Esther Valdivia , Ryan Yancy , Matthew L. McClure , Nicholas A. Kotov. In
vitro analog of human bone marrow from 3D scaffolds with biomimetic inverted
colloidal crystal geometry. Biomaterials 30 (2009) 1071–1079.
[230] Bruno E, Luikart S, Long M, Hoffman R. Marrow-derived heparan sulfate
proteoglycan mediates the adhesion of hematopoietic progenitor cells to
cytokines. Exp Hematol 1995;23: 1212–1217.
[231] Gordon M, Riley G, Watt S, Greaves M. Compartmentalization of a
haematopoietic growth factor (GM-CSF) by glycosaminoglycans in the bone
marrow microenvironment. Nature 1987;326:403–405.
[232] Gupta P, McCarthy J, Verfaillie C. Stromal fibroblast heparan sulfate is
required for cytokine-mediated ex vivo maintenance of human long-term
culture-initiating cells. Blood 1996;87: 3229–3236.
[233] Madihally S, Flake A, Matthew H. Maintenance of CD34 expression during
proliferation of CD34+ cord blood cells on glycosaminoglycan surfaces. Stem
Cells 1999;17:295–305
[234] L. Kjellen, U. Lindahl, “Proteoglycans: Structures and interactions”, Annu.
Rev. Biochem. (1991) 60, 443–475.
[235] S.V. Madihally, A.W. Flake, H.W. Matthew, “Maintenance of CD34
expression during proliferation of CD34+ cord blood cells on
glycosaminoglycan surfaces”, Stem Cells (1999) 17, 295–305.
[236] E. Ruoslahti, “Structure and biology of proteoglycans”, Annu. Rev. Cell.
Biol. (1988) 4, 229–255.
[237] I. Vlodavsky, H.Q. Miao, R. Atzmon, E. Levi, J. Zimmermann, R. Bar-Shavit,
T. Peretz, S.A. Ben-Sasson, “Control of cell proliferation by heparan sulfate and
heparin-binding growth factors”, Thromb. Haemost. (1995) 74, 534–540.
[238] S. Kiyohara, M. Sasaki, K. Saito, K. Sugita, T. Sugo, “Radiationinduced
grafting of phenylalanine-containing monomer onto a porous membrane”,
Reactive Functional Polym (1996) 31, 103-110.
[239] A. Higuchi, M. Kurihara, K. Kobayashi, C.S. Cho, T. Akaike, M. Hara,
“Albumin and urea production by hepatocytes cultured on extracellular matrix
proteins-conjugated poly(vinyl alcohol) membranes”, J. Biomat. Sci. Polym.
Edn. (2005) 16, 847–860.
[240] M. Fotino, E. Merson, F. Allen, “Micromethod for rapid separation of
lymphocytes from peripheral blood”, Ann. Clin. Lab Sci. (1971) 1, 131-133.
[241] J.W. Gratama, J. Kraan, W. Levering, D.R. Van Bockstaele, G.T. Rijkers, C.E.
Van der Schoot, “Analysis of variation in results of CD34+ hematopoietic
progenitor cell enumeration in a multicenter study”, Cytometry (1997) 30
145
109–117.
[242] H.E. Johnsen for the Nordic Myeloma Study Group Laboratories, “Report
from a Nordic workshop on CD34+ cell analysis: Technical recommendations for
progenitor cell enumeration in leukapheresis from multiple myeloma patients”, J.
Hematother. (1995) 4, 21–28.
[243] M.A. Owens, M.R. Loken, “Peripheral blood stem cell quantitation. In: Flow
Cytometric Principles for Clinical Laboratory Practice”, Wiley- Liss, New York,
(1995) 111–127.
[244] S. Siena, M. Bregni, M. Di Nicola, F. Peccatori, M. Magni, B. Brando, F.
Ravagnani, A.M. Gianni, “Milan protocol for clinical CD34+ cell estimation in
peripheral blood for autografting in patients with cancer. In: Hematopoietic Stem
Cells: The Mulhouse Manual” Alpha Med. Press, Dayton (1994) 23–30.
[245] D.R. Sutherland, L. Anderson, M. Keeney, R. Nayar, I. Chin-Yee, “The
ISHAGE guidelines for CD34+ cell determination by flow cytometry”, J.
Hematother. (1996) 5, 213–226.
[246] Tamada Y, Ikada Y: Fibroblast growth on polymer surfaces and
biosynthesis of collagen. J Biomed Mater Res. 1994; 28: 783-789.
[247] N. Fujimoto, S. Fujita, T. Tsuji, J. Toguchida, K. Ida, H. Suginami, H. Iwata,
“Microencapsulated feeder cells as a source of soluble factors for expansion of
CD34(+) hematopoietic stem cells”, Biomaterials (2007) 28, 4795–4805.
[248] W. Wagner, F. Wein, C. Roderburg, R. Saffrich, A. Faber, U. Krause, M.
Schubert, V. Benes, V. Eckstein, H. Maul, A.D. Ho, “Adhesion of hematopoietic
progenitor cells to human mesenchymal stem cells as amodel for cell-cell
interaction”, Exp. Hematol. (2007) 35, 314–325.
[249] N. Forraz, R. Pettengell, C.P. McGuckin, “Characterization of a
lineage-negative stem-progenitor cell population optimized for ex vivo
expansion and enriched for LTC-IC”, Stem Cells (2004) 22, 100–108.
[250] Zhang Z, Chen SF, Chang Y, Jiang S.,Surface grafted sulfobetaine polymers
via atom transfer radical polymerization as superlow fouling coatings, J. Phys.
Chem. B 22:10799-10804 (2006)